about
Poly(ethylmethacrylate-co-diethylaminoethyl acrylate) coating improves endothelial re-population, bio-mechanical and anti-thrombogenic properties of decellularized carotid arteries for blood vessel replacement.HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound.GABAA receptor alpha1 and alpha6 subunits mediate cell surface anchoring in cultured cells.EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancerActivin A/BMP2 chimera AB235 drives efficient redifferentiation of long term cultured autologous chondrocytes.Intra-Articular Injections of Platelet-Rich Plasma versus Hyaluronic Acid in the Treatment of Osteoarthritic Knee Pain: A Randomized Clinical Trial in the Context of the Spanish National Health Care SystemBozepinib, a novel small antitumor agent, induces PKR-mediated apoptosis and synergizes with IFNα triggering apoptosis, autophagy and senescence.Validation of suitable normalizers for miR expression patterns analysis covering tumour heterogeneity.Knee Viscosupplementation: Cost-Effectiveness Analysis between Stabilized Hyaluronic Acid in a Single Injection versus Five Injections of Standard Hyaluronic Acid.Transdifferentiation: why and how?Nanomedicine: application areas and development prospects.The impact of PKR activation: from neurodegeneration to cancer.Brown adipose tissue and novel therapeutic approaches to treat metabolic disorders.5-Fluorouracil derivatives: a patent review (2012 - 2014).How Can Nanotechnology Help to Repair the Body? Advances in Cardiac, Skin, Bone, Cartilage and Nerve Tissue RegenerationCancer suicide gene therapy: a patent review.Polymers, scaffolds and bioactive molecules with therapeutic properties in osteochondral pathologies: what's new?Clinical and therapeutic potential of protein kinase PKR in cancer and metabolism.Differentiation of intestinal epithelial cells mediated by cell confluence and/or exogenous nucleoside supplementation.Tumour malignancy loss and cell differentiation are associated with induction of gef gene in human melanoma cells.Lateral mobility and anchoring of recombinant GABAA receptors depend on subunit composition.A formulation of pancreatic pro-enzymes provides potent anti-tumour efficacy: a pilot study focused on pancreatic and ovarian cancer.Promotion of human adipose-derived stem cell proliferation mediated by exogenous nucleosides.Cardiomyogenic differentiation potential of human endothelial progenitor cells isolated from patients with myocardial infarction.Biofunctional Ionic-Doped Calcium Phosphates: Silk Fibroin Composites for Bone Tissue Engineering Scaffolding.[Factors influencing mobilisation of endothelial progenitor cells and angiogenic cytokines after an extensive acute myocardial infarction].Influence of preinfarction angina on the release kinetics of endothelial progenitor cells and cytokines during the week after infarction.Cellular extracts from post-mortem human cardiac tissue direct cardiomyogenic differentiation of human adipose tissue-derived stem cells.Revisiting the dynamic cancer stem cell model: Importance of tumour edgesThe M3/M4 cytoplasmic loop of the alpha1 subunit restricts GABAARs lateral mobility: a study using fluorescence recovery after photobleachingUltrastructural and molecular analyzes of insulin-producing cells induced from human hepatoma cellsIn vitro nanoparticle-mediated intracellular delivery into human adipose-derived stem cellsIn vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiationPancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting
P50
Q30847463-F6179C54-1E81-430F-ADDA-FC93BB92C3F8Q33976964-3B78298C-41F2-48E2-8EF6-9542BBC61828Q34326934-7C8E3C6C-223F-45CB-B894-E4B949A3F63CQ34365738-197307E6-8330-499D-8D3D-69D40F328AC5Q36275728-914535A1-1676-46E3-9740-97B22347D91FQ37134474-82DDCE75-1D8B-4B1E-B729-65097947D811Q37272761-E90E5EDD-7C4D-44A2-A5C5-6794EF7552A2Q37554494-29EBAF75-988E-4741-87A3-CE7EFE6396ABQ37729338-D1EBD8EA-5FF5-4CCB-981A-71CBE789B84EQ37854079-3FC190AA-A275-471F-BB3E-51EB1E5FAE8BQ37891690-17E84352-6E1B-4DF9-A0F5-2DBC959BE9C8Q38187546-AD65F630-9CBD-4415-8E94-D960A9B58D17Q38272618-39BB7925-EF03-4434-9AEC-E33119A5EC01Q38545641-BB990C42-460A-4B05-9874-0640CBB45DCAQ38624448-7B9C675C-8DEF-4DA0-A070-731EB8BF5FFDQ38841046-966B5999-6DC4-45AB-B45D-551FD0140E24Q38874759-BA06DBFF-B5B1-461F-81F3-56901317798CQ39445809-A576A901-3EBF-4754-B205-4E2F8C35DE4EQ39749711-6F8E3589-198A-4B25-899E-809E3F4B32E3Q39970715-6BDFEEDE-0150-49F1-8E16-69CE55E8C3F8Q40762864-9BC555CD-B7B4-41F2-B841-C24EE3D5CBDFQ42630200-4C82EBC2-8DF7-49C6-B7D2-82CBBEE10729Q43045214-DE5219DF-07A6-4305-91A3-9DDB31438CBEQ46458268-ED0D41BD-D6E5-47DE-8ABE-4144A3AFE2A4Q47800193-01301DE7-FA0D-43FF-9DDC-CBFEDC2FF8B8Q50520173-1A9A8531-4693-4B79-81D3-48CD0E53A0E6Q51575571-B56A7E98-2B3E-43C1-A039-7C2407584152Q54236755-71B314C2-DDB5-419B-8D72-032E2E0BBFF7Q57181167-5C13B25B-EBFA-483F-A83E-064D0486AC92Q79212250-4F1EF57F-D752-4122-9337-1717137F16C9Q84598275-909E5201-CD2F-478E-8A73-C89169231BA7Q86606294-7996B575-C6F6-4497-8961-BB114293AA1CQ86804768-50900DFF-F8F0-4639-AE7F-0ED4D62D938AQ92460931-A60E6531-A13C-488D-B0A8-DA1F13AAF3C1
P50
description
researcher
@en
wetenschapper
@nl
name
Macarena Peran
@en
Peran M
@nl
type
label
Macarena Peran
@en
Peran M
@nl
altLabel
Peran M
@en
prefLabel
Macarena Peran
@en
Peran M
@nl
P106
P31
P496
0000-0001-7562-2347